Sun Jinping, Xiao Di, Lang Ming, Xu Xuetao
School of Pharmacy and Food Engineering & Guangdong Provincial Key Laboratory of Large Animal Models for Biomedicine, Wuyi University, Jiangmen, 529020, China.
Mol Divers. 2025 Apr;29(2):1669-1681. doi: 10.1007/s11030-024-10943-4. Epub 2024 Aug 14.
A series of novel sulfonyl hydrazide based β-carboline derivatives (SX1-SX32) were designed and synthesized, and their structures were characterized on NMR and HRMS. Their α-glucosidase inhibitory screening results found that compounds (SX1-SX32) presented potential α-glucosidase inhibitory: IC values being 2.12 ± 0.33-19.37 ± 1.49 μM. Compound SX29 with a para-phenyl (IC: 2.12 ± 0.33 μM) presented the strongest activity and was confirmed as a noncompetitive inhibitor. Fluorescence spectra, CD spectra and molecular docking were conducted to describe the inhibition mechanism of SX29 against α-glucosidase. Cells cytotoxicity indicated SX29 (0-32 μM) had no cytotoxicity on 293T cells. In particular, in vivo experiments revealed that oral administration of SX29 could regulate hyperglycemia and glucose tolerance of diabetic mice. These achieved findings indicated that sulfonyl hydrazide based β-carboline derivatives bore promising potential for discovering new α-glucosidase inhibitors with hypoglycemic activity.
设计并合成了一系列基于磺酰肼的新型β-咔啉衍生物(SX1-SX32),并通过核磁共振(NMR)和高分辨质谱(HRMS)对其结构进行了表征。它们的α-葡萄糖苷酶抑制筛选结果表明,化合物(SX1-SX32)具有潜在的α-葡萄糖苷酶抑制活性:IC值为2.12±0.33-19.37±1.49μM。具有对苯基的化合物SX29(IC:2.12±0.33μM)表现出最强的活性,并被确认为非竞争性抑制剂。通过荧光光谱、圆二色光谱(CD)和分子对接来描述SX29对α-葡萄糖苷酶的抑制机制。细胞毒性实验表明,SX29(0-32μM)对293T细胞无细胞毒性。特别是,体内实验表明,口服SX29可以调节糖尿病小鼠的高血糖和葡萄糖耐量。这些研究结果表明,基于磺酰肼的β-咔啉衍生物在发现具有降血糖活性的新型α-葡萄糖苷酶抑制剂方面具有广阔的潜力。